(Q54577911)

1 June 2018

title

A phase II trial of PALA + dipyridamole in patients with advanced soft-tissue sarcoma. (English)

1 reference

1 June 2018

main subject

phase II clinical trial

0 references

author name string

E S Casper

1

1 reference

1 June 2018

J Baselga

2

1 reference

1 June 2018

T B Smart

3

1 reference

1 June 2018

G B Magill

4

1 reference

1 June 2018

M Markman

5

1 reference

1 June 2018

A Ranhosky

6

1 reference

1 June 2018

publication date

1 January 1991

1 reference

1 June 2018

Cancer Chemotherapy and Pharmacology

published in

1 reference

1 June 2018

volume

28

1 reference

1 June 2018

issue

1

1 reference

1 June 2018

page(s)

51-54

1 reference

1 June 2018

Plasma uridine changes in cancer patients treated with the combination of dipyridamole and N-phosphonacetyl-L-aspartate

cites work

1 reference

12 December 2020

Phase II evaluation of PALA in patients with refractory metastatic sarcomas

1 reference

12 December 2020

Phase I trial of N-(Phosphonacetyl)-L-aspartic acid (PALA)

1 reference

12 December 2020

Phase I trial of N-(phosphonacetyl)-L-aspartate

1 reference

12 December 2020

Biochemical assessment of the effects of acivicin and dipyridamole given as a continuous 72-hour intravenous infusion

1 reference

12 December 2020

Alteration of fluorouracil metabolism in human colon cancer cells by dipyridamole with a selective increase in fluorodeoxyuridine monophosphate levels

1 reference

12 December 2020

Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas

1 reference

12 December 2020

A comparison of adriamycin versus vincristine and adriamycin, and cyclophosphamide versus vincristine, actinomycin-D, and cyclophosphamide for advanced sarcoma

1 reference

12 December 2020

Phase I trial of PALA

1 reference

12 December 2020

Reversal of toxicity and antitumor activity of N-(phosphonacetyl)-L-aspartate by uridine or carbamyl-DL-asparate in vivo

1 reference

12 December 2020

An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas

1 reference

12 December 2020

Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas

1 reference

12 December 2020

Cyclophosphamide, vincristine, adriamycin, and DTIC (CYVADIC) combination chemotherapy for the treatment of advanced sarcomas.

1 reference

12 December 2020

Enhancement of fluorouracil therapy by the manipulation of tissue uridine pools

1 reference

12 December 2020

Combination chemotherapy using adriamycin, DTIC, cyclophosphamide, and actinomycin D for advanced soft tissue sarcomas: a randomized comparative trial. A phase III, Southwest Oncology Group Study (7613).

1 reference

12 December 2020

Antitumor activity of N-(phosphonacetyl)-L-aspartic acid, a transition-state inhibitor of aspartate transcarbamylase

1 reference

12 December 2020

1 reference

12 December 2020

Uridine transport in novikoff rat hepatoma cells and other cell lines and its relationship to uridine phosphorylation and phosphorolysis

1 reference

12 December 2020

Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma

1 reference

12 December 2020

High-performance liquid chromatographic analysis of dipyridamole in plasma and whole blood

1 reference

12 December 2020

Phase I clinical study of N-(phosphonacetyl)-L-aspartic acid (PALA)

1 reference

12 December 2020

Modulation of the activity of PALA by dipyridamole

1 reference

12 December 2020

Tissue-specific enhancement of uridine utilization and 5-fluorouracil therapy in mice by benzylacyclouridine.

1 reference

12 December 2020

Initial clinical study with N-(phosphonacetyl)-L-aspartic acid (PALA) in patients with advanced cancer

1 reference

12 December 2020

Reporting results of cancer treatment

1 reference

12 December 2020

A common basis for inhibition of nucleoside transport by dipyridamole and nitrobenzylthioinosine?

1 reference

12 December 2020

Binding of dipyridamole to human platelets and to alpha1 acid glycoprotein and its significance for the inhibition of adenosine uptake

1 reference

12 December 2020

Phase I trial of combination therapy of cancer with N-phosphonacetyl-L-aspartic acid and dipyridamole

1 reference

12 December 2020

Aspartate transcarbamylase. Interaction with the transition state analogue N-(phosphonacetyl)-L-aspartate

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF00684956

1 reference

1 June 2018

1 reference

1 June 2018